{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:20:48Z","timestamp":1790194848356,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40262-025-01606-0","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T19:40:56Z","timestamp":1765568456000},"page":"293-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Platform Assessment of Concentration\u2013QTc Relationship Across GalNAc\u2013siRNA Molecules"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1248-616X","authenticated-orcid":false,"given":"Prajakta","family":"Badri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiranmai","family":"Kolachana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Lasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirtha","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel J.","family":"Robbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"6","key":"1606_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1606_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"DJ Foster","year":"2018","unstructured":"Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian K, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26(3):708\u201317.","journal-title":"Mol Ther"},{"issue":"19","key":"1606_CR3","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.1093\/nar\/gkx818","volume":"45","author":"JK Nair","year":"2017","unstructured":"Nair JK, Attarwala H, Sehgal A, Wang Q, Aluri K, Zhang X, et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 2017;45(19):10969\u201377.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"1606_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown KM, Nair JK, Janas MM, Anglero-Rodriguez YI, Dang LTH, Peng H, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat Biotechnol. 2022;40(10):1500\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1606_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"24","key":"1606_CR6","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, Peiro PA, Rees DC, Stolzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289\u2013301.","journal-title":"N Engl J Med"},{"issue":"13","key":"1606_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O\u2019Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216\u201326.","journal-title":"N Engl J Med"},{"issue":"16","key":"1606_CR8","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"key":"1606_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/9780470122860.ch3","volume":"41","author":"G Ashwell","year":"1974","unstructured":"Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 1974;41:99\u2013128.","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"issue":"2 Pt 2","key":"1606_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/0092-8674(80)90371-2","volume":"22","author":"JU Baenziger","year":"1980","unstructured":"Baenziger JU, Fiete D. Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell. 1980;22(2 Pt 2):611\u201320.","journal-title":"Cell"},{"issue":"19","key":"1606_CR11","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.1016\/S0021-9258(19)70522-5","volume":"255","author":"AL Schwartz","year":"1980","unstructured":"Schwartz AL, Rup D, Lodish HF. Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J Biol Chem. 1980;255(19):9033\u20136.","journal-title":"J Biol Chem"},{"issue":"10","key":"1606_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1124\/dmd.119.087098","volume":"47","author":"D Ramsden","year":"2019","unstructured":"Ramsden D, Wu JT, Zerler B, Iqbal S, Jiang J, Clausen V, et al. In vitro drug-drug interaction evaluation of GalNAc conjugated siRNAs against CYP450 enzymes and transporters. Drug Metab Dispos. 2019;47(10):1183\u201394.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1606_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1359-6446(04)03278-7","volume":"10","author":"AM Aronov","year":"2005","unstructured":"Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today. 2005;10(2):149\u201355.","journal-title":"Drug Discov Today"},{"issue":"23","key":"1606_CR14","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1021\/jm060500o","volume":"49","author":"AM Aronov","year":"2006","unstructured":"Aronov AM. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. J Med Chem. 2006;49(23):6917\u201321.","journal-title":"J Med Chem"},{"key":"1606_CR15","unstructured":"Carito B HC, Janas M, Keirstead N, Jiang Y, Placke M. RNAi Therapeutics: ASGPR tissue expression evaluation in rat, mouse, non human primate and human. American College of Veterinary Pathologists Annual Meeting. Vancouver, BC, Canada; 2017."},{"issue":"6","key":"1606_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1124\/dmd.121.000428","volume":"50","author":"R McDougall","year":"2022","unstructured":"McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al. The nonclinical disposition and pharmacokinetic\/pharmacodynamic properties of N-acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human. Drug Metab Dispos. 2022;50(6):781\u201397.","journal-title":"Drug Metab Dispos"},{"key":"1606_CR17","unstructured":"E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Food and Drug Administration. October 2025."},{"issue":"3","key":"1606_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10928-017-9565-6","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, et al. Correction to: Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45(3):399.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1606_CR19","unstructured":"FDA Guidance: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics. June 2022."},{"issue":"5","key":"1606_CR20","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/cpt.2419","volume":"110","author":"D Vassiliou","year":"2021","unstructured":"Vassiliou D, Sardh E, Harper P, Simon AR, Clausen VA, Najafian N, et al. A drug-drug interaction study evaluating the effect of givosiran, a small interfering ribonucleic acid, on cytochrome P450 activity in the liver. Clin Pharmacol Ther. 2021;110(5):1250\u201360.","journal-title":"Clin Pharmacol Ther"},{"key":"1606_CR21","unstructured":"E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs \u2014 Questions and Answers (R3). June 2017."},{"key":"1606_CR22","unstructured":"ICH E14\/S7B Implementation Working Group Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers. Aug 2022."},{"issue":"9","key":"1606_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40264-015-0325-5","volume":"38","author":"B Darpo","year":"2015","unstructured":"Darpo B, Garnett C, Keirns J, Stockbridge N. Implications of the IQ-CSRC prospective study: time to revise ICH E14. Drug Saf. 2015;38(9):773\u201380.","journal-title":"Drug Saf"},{"issue":"2","key":"1606_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cpt.361","volume":"100","author":"C Garnett","year":"2016","unstructured":"Garnett C, Needleman K, Liu J, Brundage R, Wang Y. Operational characteristics of linear concentration-QT models for assessing QTc interval in the thorough QT and phase I clinical studies. Clin Pharmacol Ther. 2016;100(2):170\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1606_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, et al. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther. 2015;97(4):326\u201335.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1606_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/anec.12128","volume":"19","author":"B Darpo","year":"2014","unstructured":"Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, et al. The IQ-CSRC prospective clinical Phase 1 study: \u201ccan early QT assessment using exposure response analysis replace the thorough QT study?\u201d Ann Noninvasive Electrocardiol. 2014;19(1):70\u201381.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"8","key":"1606_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/0091270009337944","volume":"49","author":"B Tyl","year":"2009","unstructured":"Tyl B, Kabbaj M, Fassi B, De Jode P, Wheeler W. Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT\/QTc study: variability and sample size considerations. J Clin Pharmacol. 2009;49(8):905\u201315.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1606_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/1745691614551642","volume":"9","author":"A Gelman","year":"2014","unstructured":"Gelman A, Carlin J. Beyond power calculations: assessing type S (sign) and type M (magnitude) errors. Perspect Psychol Sci. 2014;9(6):641\u201351.","journal-title":"Perspect Psychol Sci"},{"issue":"2","key":"1606_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/dmd.122.001107","volume":"51","author":"X Jing","year":"2023","unstructured":"Jing X, Arya V, Reynolds KS, Rogers H. Clinical pharmacology of RNA interference-based therapeutics: a summary based on Food and Drug Administration-approved small interfering RNAs. Drug Metab Dispos. 2023;51(2):193\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1606_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jcph.2337","volume":"64","author":"G An","year":"2024","unstructured":"An G. Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs. J Clin Pharmacol. 2024;64(1):45\u201357.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"1606_CR31","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/cts.13391","volume":"15","author":"D Kallend","year":"2022","unstructured":"Kallend D, Mason J, Smith PF, Koren MJ, Stoekenbroek R, He Y, et al. An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: a phase I, randomized study. Clin Transl Sci. 2022;15(11):2663\u201372.","journal-title":"Clin Transl Sci"},{"issue":"7","key":"1606_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0192623318792537","volume":"46","author":"MM Janas","year":"2018","unstructured":"Janas MM, Harbison CE, Perry VK, Carito B, Sutherland JE, Vaishnaw AK, et al. The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies. Toxicol Pathol. 2018;46(7):735\u201345.","journal-title":"Toxicol Pathol"},{"issue":"1","key":"1606_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/cpt.3204","volume":"116","author":"Y Qu","year":"2024","unstructured":"Qu Y, Henderson KA, Harper TA Jr, Vargas HM. Scientific review of the proarrhythmic risks of oligonucleotide therapeutics: are dedicated ICH S7B\/E14 studies needed for low-risk modalities? Clin Pharmacol Ther. 2024;116(1):96\u2013105.","journal-title":"Clin Pharmacol Ther"},{"issue":"9841","key":"1606_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"issue":"11","key":"1606_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"KK Ray","year":"2019","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067\u201375.","journal-title":"JAMA Cardiol."},{"key":"1606_CR36","unstructured":"AMVUTTRA\u00ae(vutrisiran) prescribing information, June 2022."},{"key":"1606_CR37","unstructured":"GIVLAARI\u00ae(givosiran) prescribing information, November 2019."},{"key":"1606_CR38","unstructured":"OXLUMO\u00ae(lumasiran) prescribing information, November 2020."},{"key":"1606_CR39","unstructured":"RIVFLOZATM\u00ae (nedosiran) prescribing infotmation. September 2023."},{"issue":"2","key":"1606_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","volume":"81","author":"M Michael","year":"2023","unstructured":"Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, et al. Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial. Am J Kidney Dis. 2023;81(2):145-55.e1.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1606_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139.","journal-title":"Amyloid"},{"issue":"3","key":"1606_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","volume":"60","author":"P Badri","year":"2021","unstructured":"Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, et al. Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365\u201378.","journal-title":"Clin Pharmacokinet"},{"key":"1606_CR43","unstructured":"QFITLIA\u00ae(fitusiran) prescribing information, March 2025."},{"issue":"2","key":"1606_CR44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, Clausen VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1606_CR45","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","volume":"83","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Taubel J, Badri P, Bond S, Makarova N, Zhao W, et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83(4):838\u201348.","journal-title":"J Hepatol"},{"issue":"1","key":"1606_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77\u201389.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1606_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ymthe.2017.08.019","volume":"26","author":"JLS Willoughby","year":"2018","unstructured":"Willoughby JLS, Chan A, Sehgal A, Butler JS, Nair JK, Racie T, et al. Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression. Mol Ther. 2018;26(1):105\u201314.","journal-title":"Mol Ther"},{"issue":"2","key":"1606_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","volume":"16","author":"D Kallend","year":"2022","unstructured":"Kallend D, Stoekenbroek R, He Y, Smith PF, Wijngaard P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022;16(2):208\u201319.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"1606_CR49","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2215\/CJN.14730920","volume":"16","author":"Y Frishberg","year":"2021","unstructured":"Frishberg Y, Desch\u00eanes G, Groothoff JW, Hulton SA, Magen D, Harambat J, et al. Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol. 2021;16(7):1025\u201336.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"1606_CR50","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"1606_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","volume":"103","author":"MA Baum","year":"2023","unstructured":"Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2023;103(1):207\u201317.","journal-title":"Kidney Int"},{"issue":"1","key":"1606_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cpt.1802","volume":"108","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clin Pharmacol Ther. 2020;108(1):63\u201372.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1606_CR53","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.15270","volume":"19","author":"KJ Pasi","year":"2021","unstructured":"Pasi KJ, Lissitchkov T, Mamonov V, Mant T, Timofeeva M, Bagot C, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436\u201346.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1606_CR54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jhep.2018.03.012","volume":"69","author":"AM Turner","year":"2018","unstructured":"Turner AM, Stolk J, Bals R, Lickliter JD, Hamilton J, Christianson DR, et al. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. J Hepatol. 2018;69(2):378\u201384.","journal-title":"J Hepatol"},{"issue":"9","key":"1606_CR55","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","volume":"44","author":"W Sohn","year":"2022","unstructured":"Sohn W, Winkle P, Neutel J, Wu Y, Jabari F, Terrio C, et al. Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study. Clin Ther. 2022;44(9):1237\u201347.","journal-title":"Clin Ther"},{"issue":"3","key":"1606_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228\u201338.","journal-title":"N Engl J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01606-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:03:23Z","timestamp":1770379403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01606-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01606-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prajakta Badri, Kiranmai Kolachana, Anh Duong, Maxwell Lasko, Tirtha Nandi, Nitin Mehrotra, and Gabriel J. Robbie are or were Alnylam Pharmaceutical employees and may hold Alnylam stocks or options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"P.B., K.K., A.D., M.L., and T.N. contributed to the data analyses for this manuscript, interpretation of results, and writing and reviewing of the manuscript. N.M. and G.R. contributed to the study design, interpretation of results, and writing and reviewing of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available owing to likelihood of patient identification or other feasibility issues, but may be available from the corresponding author on reasonable request and upon approval by Alnylam.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study was conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonization, the Declaration of Helsinki, and all applicable federal and local regulations. The study was approved by independent institutional review boards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Written informed consent was obtained from each subject before any study-related procedures were performed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}